Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]-INCB123667 in Healthy Male Participants

Part of paid clinical trials in Madison, Wisconsin.

Sponsor
Incyte Corporation
Study ID
NCT07218744
Phase
PHASE1
Status
Completed

Conditions

  • Healthy Participants

Eligibility Criteria

Sex
MALE
Age
18 Years - 55 Years
Healthy Volunteers
Accepted

Interventions

  • INCB123667 — DRUG
    INCB123667 will be administered orally as a tablet dose, followed approximately 10 minutes later by an oral dose solution of radiolabeled INCB123667.

Study Details

This study will assess the mass balance, pharmacokinetics, and metabolite profiles of a single oral dose of \[14C\] INCB123667 in healthy male participants.

Key Dates

First listed
Oct 20, 2025
Start date
Nov 13, 2025
Status verified
Jan 2026
Primary completion
Dec 10, 2025
Completion
Dec 10, 2025

Study Design

Enrollment
9 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment: INCB123667
    Participants will be administered INCB123667 tablet orally, followed approximately 10 minutes later by an oral dose solution of radiolabeled INCB123667.

Primary Outcome Measure

Total Recovery (Urine + Feces) of the Administered Radioactivity [ Time Frame: Approximately 2 weeks ]

Locations (1)

FacilityCityStateZIPSite coordinators
Fortrea Clinical Research Unit Ltd Labcorp Clinical Research Unit Limited MadisonMadisonWisconsin53704-

Find similar trials in Madison, WI

By research site
Fortrea Clinical Research Unit Ltd Labcorp Clinical Research Unit Limited Madison· Madison, WI

Related Studies